Form 4 for COLL COLLEGIUM PHARMACEUTICAL, INC
Accepted 2023-12-20 00:00:00 ET · period of report 2023-12-18 · accession 0001062993-23-022977 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-20 | 2023-12-18+ | COLL | Ciaffoni Joseph | Pres, CEO, Dir | S - Sale+OE | $30.18 | -68.8K | 275.0K | -20% | -$2.08M |
| DM | 2023-12-20 | 2023-12-18+ | COLL | Ciaffoni Joseph | Pres, CEO, Dir | M - OptEx | $21.34 | +68.8K | 302.8K | +29% | +$1.47M |
| DM | 2023-12-20 | 2023-12-18+ | COLL | Ciaffoni Joseph | Pres, CEO, Dir | M - OptEx | $0.00 | -68.8K | 62.2K | -53% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-20 | S | D | 26,454 | $30.40 | 275,000 | D | — | — | (F4) The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.64, inclusive. |
| 2 | Common | Common Stock | 2023-12-20 | M | A | 26,454 | $21.34 | 301,454 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-19 | M | A | 14,516 | $21.34 | 289,516 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-18 | M | A | 27,798 | $21.34 | 302,798 | D | — | — | |
| 5 | Common | Common Stock | 2023-12-18 | S | D | 27,798 | $30.04 | 275,000 | D | — | — | (F2) The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. |
| 6 | Common | Common Stock | 2023-12-19 | S | D | 14,516 | $30.03 | 275,000 | D | — | — | (F3) The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.185, inclusive. |
| 7 | Derivative | Stock Option (Right to Purchase) | 2023-12-19 | M | D | 14,516 | $0.00 | 47,686 | D | $21.34 · — to 2030-02-05 | 14,516 Common Stock | (F5) Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer. |
| 8 | Derivative | Stock Option (Right to Purchase) | 2023-12-20 | M | D | 26,454 | $0.00 | 21,232 | D | $21.34 · — to 2030-02-05 | 26,454 Common Stock | (F5) Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer. |
| 9 | Derivative | Stock Option (Right to Purchase) | 2023-12-18 | M | D | 27,798 | $0.00 | 62,202 | D | $21.34 · — to 2030-02-05 | 27,798 Common Stock | (F5) Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer. |